Analysis toolkit for evaluation of drug titration practice in acute lymphoblastic leukemia maintenance

被引:0
|
作者
Mungle, Tushar [1 ,2 ]
Mahadevan, Ananya [2 ]
Mukhopadhyay, Jayanta [3 ]
Das Bhattacharya, Sangeeta [1 ]
Saha, Vaskar [2 ,4 ,5 ]
Krishnan, Shekhar [2 ,4 ,5 ]
机构
[1] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India
[2] Tata Med Ctr, Tata Translat Canc Res Ctr, 14 Major Arterial Rd E West, Kolkata 700160, W Bengal, India
[3] Indian Inst Technol Kharagpur, Dept Comp Sci & Engn, Kharagpur 721302, W Bengal, India
[4] Tata Med Ctr, Dept Paediat Haematol & Oncol, Kolkata 700160, W Bengal, India
[5] Univ Manchester, Fac Biol Med Hlth, Sch Med Sci, Div Canc Sci, Manchester M13 9PL, England
关键词
acute lymphoblastic leukemia; maintenance therapy; drug titration; visualization and analysis; protocol compliance; RELAPSE; THERAPY;
D O I
10.1093/jamiaopen/ooae089
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective During the 2-year maintenance treatment phase (MT) of acute lymphoblastic leukemia (ALL), personalized patient-specified titration of oral antimetabolite drug doses is required to ensure maximum tolerated systemic drug exposure. Drug titration is difficult to implement in practice and insufficient systemic drug exposure resulting from inadequate dose titration increases risk of ALL relapse.Materials and Methods We developed an open-source R-based analytical toolkit, including the allMT R package and an interactive web-based R Shiny VIATAMIN application, to evaluate antimetabolite drug titration during MT.Results Evaluation is initiated with basic visualization analysis of drug titration, in both individual patients and patient cohorts. Observations are supplemented with descriptive analyses of hematological toxicity frequency and prescriber compliance rates with protocol drug titration rules. In individual patients, visual and quantitative analyses indicate recurring potentially correctable suboptimal drug titration patterns. In patient cohorts, the toolkit enables evaluation of the impact of interventions to optimize MT drug titration.Discussion Incorporation of the toolkit in a forthcoming clinical decision support system for MT would enable real-time examination and course correction of drug titration practice.Conclusion Future versions will be enhanced to include other variables that influence drug titration practice, including clinical toxicity data and later, pharmacological markers of antimetabolite, adherence, and drug activity. Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Many children are cured with modern treatment. Treatment typically lasts 2.5 years, including a critical 2-year maintenance phase where children take oral anti-cancer drugs. To ensure optimal treatment, drug doses during the maintenance phase must be adjusted carefully for each child, a process called drug titration. This requires regular blood tests and close monitoring of treatment history. Drug titration is a challenging task and clinical practitioners currently lack specialized tools to efficiently manage this process. To address this requirement, we have developed open-source tools to help visualize drug titration patterns and identify opportunities to improve titration practice. These tools also help highlight when children may be experiencing difficulties tolerating drug treatment. We anticipate that these tools will enhance patient care during the maintenance treatment phase by providing insights into treatment patterns and by highlighting potential areas for improvement in practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] EVALUATION OF INTENSIFICATION AND MAINTENANCE PROGRAMS IN TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
    SACKMANNMURIEL, F
    SVARCH, E
    EPPINGERHELFT, M
    BRAIER, JL
    PAVLOVSKY, S
    GUMAN, L
    VERGARA, B
    PONZINIBBIO, C
    FAILACE, R
    GARAY, GE
    BUGNARD, E
    OJEDA, FG
    DEBELLIS, R
    DESIJVARGER, SR
    SASLAVSKY, J
    CANCER, 1978, 42 (04) : 1730 - 1740
  • [2] EVALUATION OF INTENSIFICATION AND MAINTENANCE COMBINATION IN ACUTE LYMPHOBLASTIC LEUKEMIA(ALL)
    PAVLOVSKY, S
    SACKMANN, F
    EPPINGER, M
    SVARCH, E
    BRAIER, JL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 7 - 7
  • [3] EVALUATION OF INTENSIFICATION AND MAINTENANCE PROGRAMS IN TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
    MURIEL, FS
    EPPINGERHELFT, M
    GUMAN, L
    PAVLOVSKY, S
    BRAIER, JL
    PONZINIBBIO, C
    FAILACE, R
    GARAY, GE
    BUGNARD, E
    DESIJVARGER, SR
    OJEDA, FG
    SASLAVSKY, J
    MEDICINA-BUENOS AIRES, 1976, 36 (06) : 567 - 567
  • [4] EVALUATION OF INTENSIFICATION AND MAINTENANCE PROGRAMS IN TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    MURIEL, FS
    HELFT, ME
    PAVLOVSKY, S
    BRAIER, JL
    HIDALGO, G
    BUGNARD, E
    OJEDA, F
    FAILACE, R
    SVARCH, E
    JOURNAL OF PEDIATRICS, 1976, 89 (02): : 320 - 321
  • [5] ADRIAMYCIN AS A MAINTENANCE AGENT IN ACUTE LYMPHOBLASTIC LEUKEMIA
    HVIZDALA, EV
    KOMP, DM
    RAGAB, AH
    CRIST, WM
    PEDIATRIC RESEARCH, 1978, 12 (04) : 466 - 466
  • [6] Stability Analysis of Equilibria for a Model of Maintenance Therapy in Acute Lymphoblastic Leukemia
    Badralexi, Irina
    Halanay, Andrei-Dan
    Mghames, Ragheb
    MATHEMATICS, 2022, 10 (03)
  • [7] REMISSION MAINTENANCE OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
    ARMITAGE, JO
    BURNS, CP
    MEDICAL AND PEDIATRIC ONCOLOGY, 1977, 3 (01): : 53 - 58
  • [8] EVALUATION OF LIVER PERFORMANCE DURING MAINTENANCE MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN
    MANCINI, AF
    ROSITO, P
    VECCHI, V
    VIVARELLI, F
    FALDELLA, G
    DELUCA, M
    MINERVA PEDIATRICA, 1977, 29 (36) : 2133 - 2142
  • [9] IS MAINTENANCE THERAPY NECESSARY FOR ACUTE LYMPHOBLASTIC-LEUKEMIA
    SESHADRI, R
    TURNER, DR
    LANCET, 1986, 2 (8504): : 452 - 453
  • [10] Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer
    Shekhar Krishnan
    Ananya Mahadevan
    Tushar Mungle
    Manash Pratim Gogoi
    Vaskar Saha
    Indian Journal of Pediatrics, 2024, 91 : 47 - 58